Windsor, Sheryl L.

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 618

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial

Nassif, M. E., Windsor, S. L., Tang, F., Khariton, Y., Husain, M., Inzucchi, S. E., McGuire, D. K., Pitt, B., Scirica, B. M., Austin, B., et al. (2019) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 424

Safety and efficacy of Omacor in severe hypertriglyceridemia

Harris, W. S., Ginsberg, H. N., Arunakul, N., Shachter, N. S., Windsor, S. L., Adams, M., Berglund, L., & Osmundsen, K. (1997) · Journal of Cardiovascular Risk

Lipoproteins and Cardiovascular HealthFatty Acid Research and Health

Cited by 252

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): A randomised, double-blind, placebo-controlled, phase 3 trial

Kosiborod, M. N., Esterline, R., Furtado, R. H. M., Oscarsson, J., Gasparyan, S. B., Koch, G. G., Martinez, F., Mukhtar, O., Verma, S., Chopra, V., et al. (2021) · The Lancet Diabetes & Endocrinology

COVID-19 Clinical Research StudiesDiabetes Treatment and Management

Cited by 243

Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans

Rambjør, G. S., W»len, A. I., Windsor, S. L., & Harris, W. S. (1996) · Lipids

Fatty Acid Research and HealthAquaculture Nutrition and Growth

Cited by 147